Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal
Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it broadens its pipeline.
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion.
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.
Lilly nets Scorpion cancer drug in $2.5bn licensing deal
Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JPMorgan healthcare conference.
Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.
Lilly takes a nibble at Scorpion program
US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech developing small molecule precision oncology therapies.
JPM25: Eli Lilly strikes $2.5B Scorpion buyout in twist to breast cancer tale
Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’ PI3Kα pipeline for up to $2.5 billion.
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive agreement for Lilly to acquire Scorpion's PI3Kα inhibitor program STX-478.
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for up to $2.5 billion
Eli Lilly said on Monday it would buy cancer therapy developer Scorpion Therapeutics for up to $2.5 billion in cash. Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors.
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...
Hosted on MSN18h
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478.